Muscarinic Acetylcholine Receptor Market Overview
Muscarinic Acetylcholine Receptor market size is forecast to reach $1.89 billion by 2026, growing at a CAGR of 4.1% during the forecast period 2021-2026. Muscarinic Acetylcholine Receptor are kind of receptors that are involved in regulating the number of peripheral and central functions and are able to inhibit postsynaptic neurons. They are responsible for mediating the effects basically the physiological effects of the nerve activity that are parasympathetic. It has both inhibitory as well as excitatory effects that can block or stimulate the response and is stored in the acetylcholine producing neurons as cholinergic neurons. It is an ester of acetic acid and choline that functions to transmit nerve impulses within the peripheral and central nervous systems. Increasing prevalence of disease such as chronic obstructive pulmonary disease and increasing importance of muscarinic acetylcholine disease therapeutics are the major factors driving the growth of the market. Growth in research in muscarinic acetylcholine and rise in the adoption of muscarinic acetylcholine receptor is set to further enhance the overall market development of the Muscarinic Acetylcholine Receptor Market for the period 2021-2026.
Muscarinic Acetylcholine Receptor Market Report Coverage
The report: “Muscarinic Acetylcholine Receptor Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Muscarinic Acetylcholine Receptor Market.
By Product: Tropicamide, Anauex-273, Nu-0467154, and Others.
By Test : M1, M4, M5, and Others.
By Application: Chronic Obstructive Pulmonary Disease, Attention Deficit Hyperactivity Disorder, Alzheimers Disease, Memory Impairment, and Psychiatric Disorders.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, and Rest of South America), and Rest of the World (Middle East, and Africa).
Key Takeaways
North America dominated the Muscarinic Acetylcholine Receptor Market in 2020 owing to the increasing number of key players who are continuously focusing on developing M1 mAchR agonists for treating Alzheimer’s disease and increasing number of pharmaceutical companies that are working on new therapies for rare neurological conditions. The Muscarinic Acetylcholine Receptor Market scope for different regions will be provided in the final report.
Growing public awareness and technological advancements along with rising awareness about muscarinic acetylcholine & its prevention are likely to aid the market growth of the Muscarinic Acetylcholine Receptor Market report.
Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Muscarinic Acetylcholine Receptor Market report.
Inadequate funding and high cost involved in the treatment of the diseases is poised to create the hurdles for the Muscarinic Acetylcholine Receptor Market.
Muscarinic Acetylcholine Receptor Market Revenue Share, By Geography, 2020(%)
For More Details on This Report – Request for Sample
Muscarinic Acetylcholine Receptor Market Segment Analysis – By Product
Tropicamide held the largest share in the Muscarinic Acetylcholine Receptor Market in 2020 and is estimated to grow at a CAGR of 4.4% during the forecast period 2021-2026. Tropicamide is a muscarinic antagonist having similar actions to atropine with an anticholinergic property. It binds the muscarinic receptors in the ciliary muscle in the eye and in the sphincter. It inhibits the responses from stimulation and produces the dilation of the pupil along with the paralysis of the ciliary muscle. Tropicamide is a diagnostic agent that is used to produce short duration cycloplegia and mydriasis. Owing to the short duration of the effect, it is used during dilated fundus examination. Cycloplegic drops are used to treat uveitis that decreases the risk of synechiae and decreases the inflammation in the anterior chamber of the eye. Tropicamide are estimated to register the higher CAGR over the period 2021-2026.
Muscarinic Acetylcholine Receptor Market Segment Analysis – By Application
Chronic Obstructive Pulmonary Disease held the largest share in the Muscarinic Acetylcholine Receptor Market in 2020 and is estimated to grow at a CAGR of 4.3% during the forecast period 2021-2026. Muscarinic acetylcholine receptor controls smooth muscle tone, inflammation, and mucus secretion in healthy lungs. Cholinergic mechanisms contribute to increase mucus secretion and bronochoconstriction in chronic obstructive pulmonary disease. Muscarinic acetylcholine is not a neurotransmitter but it transcends the parasympathetic nervous system that can modify the phenotypic function of airway cells including the epithelial cells. Chronic Obstructive Pulmonary Disease are estimated to register the higher CAGR over the period 2021-2026.
Muscarinic Acetylcholine Receptor Market Segment Analysis – By Geography
North America dominated the Muscarinic Acetylcholine Receptor Market with a major share of 41.8% in 2020. This is attributed to the increasing number of key players that are focusing on developing mAChR for the treatment of Alzeheimers’s disease and increasing number of pharmaceutical companies that are working on new therapies for neurological conditions. Increasing incidences of chronic obstructive pulmonary disease and increased research activity for therapeutic contribution of these receptors are also increasing the growth of the market in this region.
However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2021-2026 owing to the increase in healthcare expenditure and rise in the demand for new treatment for Alzeheimer’s disease.
Muscarinic Acetylcholine Receptor Market Drivers
Increasing Prevalence of Chronic Obstructive Pulmonary Disease
Increasing prevalence of chronic obstructive pulmonary disease is increasing the growth of the Muscarinic Acetylcholine Receptor Market. Chronic obstructive pulmonary disease causes obstructed airflow from the lungs which includes difficulty in breathing, mucus, and cough. It is mainly caused by long term exposure to particulate matter and irritating gases. People suffering from this have high risk of developing heart disease, and variety of other conditions. Two most common conditions that contribute to it are Emphysema and chronic bronchitis which usually occurs together. It affects 2 to 8% of the population. Thus, increasing the growth of the Muscarinic Acetylcholine Receptor Market during the forecast period 2021-2026.
Rising Awareness About Muscarinic Acetylcholine Receptor
Rising awareness about muscarinic acetylcholine receptor is increasing the growth of the Muscarinic Acetylcholine Receptor Market. Neurotransmitter acetylcholine recognized by muscarinic receptors that translates into electrical transients and altered cell behavior by suppressing the signaling pathways. Awareness is rising among the people that it decreases the heart rate and helps in bronchial construction. It makes to breath in asthmatics and enhances the urination by relaxing and contracting the bladder.Thus, increasing the growth of the Muscarinic Acetylcholine Receptor Market during the forecast period 2021-2026.
Muscarinic Acetylcholine Receptor Market Challenges
Inadequate funding and high cost involved in the treatment of the diseases
Some of the factors that are set to impede the growth of the Muscarinic Acetylcholine Receptor Market are inadequate funding and high cost involved in the treatment of the disease. Strict approval process is also set to hinder the growth of the market.
Muscarinic Acetylcholine Receptor Market Landscape
Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Muscarinic Acetylcholine Receptor Market. In 2020, the Muscarinic Acetylcholine Receptor Market share is consolidated by the top ten players present in the market. The Muscarinic Acetylcholine Receptor Market, top 10 companies are Heptares Therapeutics Ltd., Astrazeneca Plc, Karuna Pharmaceuticals Inc., Anavex Life Sciences Corp., NeuroHealing Pharmaceuticals Inc. and Sumitomo Dainippon Pharma Co. Ltd. among others.